本帖最后由 老马 于 2012-1-13 21:20 编辑
) C6 e; h" p- ?/ @
7 R5 G& S4 l( T ^6 {+ e爱必妥和阿瓦斯丁的比较% y4 n' J# @; e+ _" ^9 W0 n
8 o( X, W3 R# j G Q( o6 Q1 Bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
9 B2 s( x) x$ n0 K% t6 `
9 q" ^& h6 ]% D* s& l. m" u6 g+ q$ k2 F
! C* K1 y" A! z/ _ O# e( n
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
6 S; x H" h8 b9 Q==================================================! g- {( d5 \* b( {* S. K4 B7 ~4 K
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL): Q6 Z* Z6 W7 F* p3 w; f: L
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point." ?; y& {3 s+ w$ p5 {7 w3 G* }
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
m* J4 t5 d9 H, L! w
|